In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Michael McCaughan

Michael McCaughan has has 25 years of experience providing analysis and insight about the biopharma industry, including 10 years as Editor-In-Chief of The Pink Sheet and The Pink Sheet DAILY. He speaks frequently on regulatory and policy developments affecting the industry.

Latest From Michael McCaughan

The $4 Million NDA: US FDA User Fees After 30 Years

The cost of filing a New Drug Application with the US FDA has pushed above the $4 million mark. That is a remarkable rate of increase from the original $100,000 fee set in 1992 – but it does buy a lot more.

User Fees Drug Review

Medicare Copay ‘Smoothing’ Plan Shows Nothing Is Simple In Part D

Guidance on how to implement a new policy to permit Part D beneficiaries to pay high copays in monthly installments (rather than all at once at the pharmacy counter) shows that there is no such thing as a straight-forward change in the drug benefit program.

Medicare Reimbursement

US Price Negotiation Pioneers: The Unique Position Of Imbruvica

The first 10 drugs picked for price negotiation in the US Medicare program will all be unwilling trailblazers. But the position of Abbvie’s Imbruvica stands out as unique in several important ways.

Medicare Pricing Debate

Price Negotiation And The GLP1 Class: Trulicity Lucky To Be A BLA

The inaugural class of drugs subject to the new US Medicare price negotiation process includes four antidiabetics. But none are from the biggest and fastest growing class – thanks to few technicalities in how the law works.

Medicare Reimbursement

The US FDA Committee ‘Hearing’ Is Dead! Long Live The Committee Hearing!

The US FDA is free from the need to reconsider Accelerated Approvals in a formal hearing in front of an advisory committee. But now the agency is now trying that approach to hear an appeal of a rejected application.

Advisory Committees Drug Approval Standards

Medicare Floats Essential Medicine ‘Buffer Stock’ Incentive For Hospitals

The US is proposing to pay hospitals extra to maintain reserve supplies of ‘essential medicines’ to help mitigate shortages. But would the plan only make the problem worse?

Manufacturing Medicare
See All
UsernamePublicRestriction

Register